| Medical and Health Sciences | 2021-2025 | 513 | HU 2 | 99.89 |
| Surgery | Lifetime | 152 | HU 2 | 99.87 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 187 | HU 1 | 99.44 |
| Cardiology and Cardiovascular Medicine | Lifetime | 720 | HU 3 | 98.61 |
| Cancer Research | Lifetime | 431 | HU 2 | 97.37 |
| Clinical Biochemistry | Lifetime | 739 | HU 5 | 82.90 |
| Internal Medicine | Lifetime | 593 | HU 1 | 60.13 |
| Surgery | 2021-2025 | 24 | HU 1 | 99.86 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 216 | HU 1 | 96.12 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 440 | HU 2 | 94.38 |
| Cancer, Lipids, and Metabolism | Lifetime | 90 | HU 2 | 99.51 |
| Lipoproteins and Cardiovascular Health | Lifetime | 81 | HU 1 | 99.53 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 93 | HU 2 | 99.57 |
| Pharmaceutical Economics and Policy | Lifetime | 43 | HU 1 | 98.91 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 235 | HU 1 | 99.28 |
| Lipid metabolism and disorders | Lifetime | 55 | HU 2 | 99.05 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 408 | HU 1 | 98.18 |
| Cardiovascular Disease and Adiposity | Lifetime | 464 | HU 2 | 97.69 |
| Diabetes Treatment and Management | Lifetime | 568 | HU 1 | 97.98 |
| Cholesterol and Lipid Metabolism | Lifetime | 332 | HU 2 | 96.71 |
| Fatty Acid Research and Health | Lifetime | 684 | HU 3 | 95.78 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 809 | HU 2 | 95.37 |
| Paraoxonase enzyme and polymorphisms | Lifetime | 170 | HU 3 | 90.10 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 22 | HU 1 | 99.51 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 22 | HU 1 | 99.22 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 173 | HU 1 | 97.90 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 121 | HU 2 | 95.98 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 273 | HU 1 | 88.99 |
| Lipid metabolism and disorders | 2021-2025 | 124 | HU 1 | 87.22 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 914 | HU 4 | 81.78 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 686 | HU 1 | 80.40 |
| Cholesterol and Lipid Metabolism | 2021-2025 | 228 | HU 1 | 76.66 |
| Pharmaceutical Economics and Policy | 2021-2025 | 862 | HU 11 | 72.01 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 402 | HU 3 | 63.90 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 676 | HU 1 | 61.29 |
